The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Prices for some generics are rising, thanks to limited competition.
UnitedHealthcare finds drug costs more than doubled.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
Drug quality problems and shortages are behind the shift that will affect antibiotics, painkillers and vitamins.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
The professional association says it's necessary, because high prices do not indicate impact.
The UK's National Institute for Health and Care Excellence says it bounced Bayer's drug for failing to compare itself to current treatments, and Sanofi's over cost.
Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.
The UK watchdog wants to know what's behind the rare-disease drug's high price.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
The third Pharmacy Benefit Management Institute specialty medication survey expects specialty medications, which average around $3,000 per month per patient, will account for 50% of the drug spend within four or five years.
The drug maker is reportedly talking low rates for India's market.
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
Our year-end list captures the 10 that sparked heaviest interest.
The drugmaker and partner AstraZeneca say they can't find a comfortable pricing arrangement with German insurers.
The National Health Service is expected to have a $49-billion deficit by 2020.
The PBM encourages step-therapy to control costs.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.